← Back

Wire · opportunities

Will Asundexian Change Secondary Stroke Prevention?

Published

11 November 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at medscape.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

The FDA approved asundexian, the first factor XIa inhibitor, for secondary prevention of stroke in adults with recent noncardioembolic ischemic stroke or high-risk transient ischemic attack, based on the OCEANIC-STROKE trial showing a 26% reduction in recurrent ischemic stroke without significant increase in major bleeding. China was the first country to approve the drug, marking a regulatory milestone for this new class of anticoagulants.

This Wire brief sits within Fusion42's coverage of Health, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.

◆ ◆ The Wire takeaway

You can now offer stroke prevention treatment that lowers recurrent risk without a major bleeding increase. Competitors using older anticoagulants face urgent pressure as this new drug opens a safer door for secondary stroke patients.

◆ Coverage

15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026

◆ Related on Wire

◆ Topics

Healthfactor-xiastroke-preventionFDA-approvalanticoagulantsclinical-trial